文献速递脑血管病

癌症合并缺血性卒中成人抗凝使用与血栓栓塞事件风险

Anticoagulant Usage and Risk of Thromboembolic Events After Ischemic Stroke in Adults With Cancer.
PubMed 文献 · Neurology · 2025-10-30

这项回顾性队列研究利用Optum数据库分析2020年10月至2021年9月因缺血性卒中住院的活动性癌症成人,发现卒中患者中活动性癌症占10.2%,出院后抗凝药配药率仅14.7%。倾向评分匹配后,抗凝处方与未抗凝处方的血栓栓塞复发风险(HR 1.21;95%CI 0.91-1.61)及大出血风险(HR 1.13;95%CI 0.78-1.63)均无统计学差异。

要点

  • 缺血性卒中患者中约10.2%合并活动性癌症,以泌尿生殖系统、胃肠道和血液系统肿瘤最常见。
  • 活动性癌症合并缺血性卒中患者出院后抗凝药配药率仅14.7%,血栓栓塞复发和大出血风险均较高。
  • 倾向评分匹配后,抗凝处方与未抗凝处方的血栓栓塞复发及大出血风险均无统计学差异。

核心结论

  • 活动性癌症合并缺血性卒中患者短期血栓栓塞复发和大出血风险均较高,但抗凝药处方与未处方者的血栓栓塞复发及大出血风险无统计学差异。

研究设计与样本

  • 回顾性队列研究,使用Optum去标识化Clinformatics Data Mart数据库,纳入2020年10月至2021年9月因缺血性卒中住院的活动性癌症成人。
  • 共识别86,365例缺血性卒中患者,其中10.2%有活动性癌症;经 eligibility 筛选后4,781例纳入主分析,中位年龄74岁(IQR 68-81),48%为女性。

主要发现

  • 活动性癌症类型分布:34%泌尿生殖系统、25%胃肠道、23%血液系统。
  • 抗凝药配药率为14.7%;血栓栓塞事件复发发生率为38.4/100人年(95%CI 35.4-41.6),大出血事件发生率为20.9/100人年(95%CI 18.8-23.4)。
  • 倾向评分匹配后,抗凝处方与未处方者的血栓栓塞复发风险无统计学差异(HR 1.21;95%CI 0.91-1.61)。
  • 抗凝处方与大出血风险也无统计学差异(HR 1.13;95%CI 0.78-1.63)。

临床怎么用

  • 活动性癌症合并缺血性卒中患者出院后抗凝药使用率低,且本研究中抗凝处方未显示与血栓栓塞复发或大出血风险改变相关,临床决策需个体化权衡。

局限性

  • 存在适应证混杂可能;需要临床试验进一步评估该高危人群的最佳抗血栓策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Ischemic stroke and cancer often coexist. The aim of this study was to determine the prevalence of cancer among patients with stroke, their antithrombotic treatment patterns, and the risk of subsequent thromboembolic events in a large population-based cohort. METHODS: This retrospective cohort study used data from Optum's deidentified Clinformatics Data Mart Database to assess the 6-month risk of recurrent thromboembolic and major bleeding events identified using validated International Classification of Diseases code algorithms, among adults with active cancer hospitalized with ischemic stroke between October 2020 and September 2021. In addition, we explored the risk of recurrent thromboembolic events stratified by anticoagulant exposure. Landmark analyses were undertaken with anticoagulant exposure status based on dispensations in the week after hospital discharge. Propensity score matching aimed to minimize selection bias between the groups. Hazard ratios (HRs) were estimated using Cox proportional hazard models with robust variance estimators to account for clustering within propensity score-matched pairs. RESULTS: Among 86,365 patients identified with ischemic stroke, 10.2% had active cancer (most common types: 34% genitourinary, 25% gastrointestinal, 23% hematologic). After applying eligibility criteria, 4,781 patients were included in the main analysis (median age 74 [interquartile range 68-81] years; 48% female). Anticoagulants were dispensed to 14.7% of patients. The incidence of thromboembolic event recurrence and major bleeding events was 38.4 (95% CI 35.4-41.6) and 20.9 (95% CI 18.8-23.4) per 100 person-years, respectively. After propensity score matching, the risk of thromboembolism recurrence was not statistically different between those with and without anticoagulant prescription (HR 1.21; 95% CI 0.91-1.61). Anticoagulant prescription was also not associated with a higher risk of major bleeding events (HR 1.13; 95% CI 0.78-1.63). DISCUSSION: In this large-scale study, approximately 10% of patients with ischemic stroke had active cancer and they faced a markedly elevated short-term risk of recurrent thromboembolism and major bleeding events. Anticoagulants were infrequently prescribed after discharge and did not differentially affect the rate of ischemic or bleeding outcomes compared with alternative treatment strategies, although confounding by indication is likely. Clinical trials are required to further assess optimal antithrombotic strategies in this high-risk population.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Balali P, Acton EK, Elser H, et al. Anticoagulant Usage and Risk of Thromboembolic Events After Ischemic Stroke in Adults With Cancer. Neurology. 2025. PMID: 41166668. doi:10.1212/WNL.0000000000214325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。